Clinical Trial

Experimental Treatment for Myeloma and Non Hodgkin Lymphoma

Study Description

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or relapsed/refractory CD20-positive non-Hodgkin lymphoma (NHL). The primary endpoint of the study is to determine the maximum tolerated dose (MTD) of NAM-NK cells while maintaining safety.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells

Cyclophosphamide 40 mg/kg x 1 day on Day -5 Fludarabine 25 mg/m^2 x 3 days (Day -5, Day -4, day-3)

Additional Information

Official Study Title

A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma

Clinical Trial ID

NCT03019666

ParticipAid ID

NbWXQd